Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7664800 | 0.85 | PDE4B (0.38) | NPC1RAB9A | |
| SCHEMBL7669209 | 0.82 | CNR1 (0.44) | NPC1RAB9AKMT2AMEN1CNR1 | |
| SCHEMBL7663028 | 0.82 | KDR (0.35) | NPC1RAB9AKMT2AMEN1RAF1 | |
| SCHEMBL7665356 | 0.81 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL7673254 | 0.81 | LOXL2 (0.36) | KITRAF1BRAF | |
| SCHEMBL7669858 | 0.79 | EGFR (0.49) | MAOBKIT | |
| SCHEMBL7673416 | 0.78 | MAP4K4 (0.37) | — | |
| SCHEMBL7671184 | 0.78 | CNR1 (0.40) | NPC1RAB9ACNR1 | |
| SCHEMBL7673525 | 0.78 | RAB9A (0.33) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7669005 | 0.77 | CNR1 (0.38) | NPC1RAB9ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | P2RX7 3462/4885NPC1 710/4885RAB9A 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.